Organization (Industry)
Toray Industries, Inc. (Japan)
ClinicalTrials.gov lists Toray Industries, Inc. (Japan) as lead sponsor of 18 trials, counting the companies grouped under it. Toray Industries, Inc. (Japan) itself has 144 active development programs and 15 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Toray K.K., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Toray Industries, Inc. (Japan) and 1 company grouped under it: 18 lead-sponsored trials (18 its own, 0 in the grouped companies) and 4 legal-entity registrations (1 its own, 3 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Toray (Thailand) | 0 | 3 |
Disease areas (29)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Kidney Failure, Chronic | 3 |
| Renal Insufficiency, Chronic | 3 |
| Cholangiocarcinoma | 2 |
| Colorectal Neoplasms | 2 |
| Melanoma | 2 |
Showing 5 of 29 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 3 |
| 2016 | 2 |
| 2013 | 1 |
| 2012 | 2 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (144)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| RAMUCIRUMAB | Stomach Neoplasms | Phase 2 | 2 |
| TRK-950 | Stomach Neoplasms | Phase 2 | 2 |
| (nab)-paclitaxel | Stomach Neoplasms | Phase 2 | 2 |
| NIVOLUMAB | Melanoma | Phase 1/2 | 2 |
| TRK-950 | Melanoma | Phase 1/2 | 2 |
Showing 5 of 144 active programs.
Approved assets (15)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| RAMUCIRUMAB | 2 |
| (nab)-paclitaxel | 2 |
| Nalfurafine | 1 |
| NIVOLUMAB | 2 |
| BEVACIZUMAB | 1 |
Showing 5 of 15 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 40% hit target (n=5) | 1 of 4 on time (n=4) |
Journals published in (7)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMC nephrology | 2 |
| The Cochrane database of systematic reviews | 2 |
| Cancer research communications | 1 |
| Circulation. Arrhythmia and electrophysiology | 1 |
| Hepatology research : the official journal of the Japan Society of Hepatology | 1 |
Showing 5 of 7 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 3,506 | 518 | 2025-12-30 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Toray Industries Inc. | Masaki, JP | EMA | |
| TORAY INDUSTRIES, INC. | CHUO-KU T?ky?, JP | FDA |
Latest dated events (3,529)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-09 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 3,529 events.
Biomarker capability evidence (32)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BRCA1 | Trial sponsor | Named in trial inclusion criteria |
| CAPRIN1 | Trial sponsor | Named in trial inclusion criteria |
| NTRK1 | Trial sponsor | Named in trial inclusion criteria |
| NTRK1 | Trial sponsor | Named in trial inclusion criteria |
| PDCD1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 32 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.